MarketPulse

clonoSEQ

2 articles
The Motley FoolThe Motley Fool··Cory Renauer

ADPT Executive's $826K Share Sale Signals Liquidity Play, Not Loss of Confidence

$ADPT's President/COO sold $826K in shares via option exercise while retaining 408K shares. MRD revenue grew 46%; Medicare coverage expansion supports growth outlook.
ADPTexecutive compensationbiotechnology
The Motley FoolThe Motley Fool··Seena Hassouna

Adaptive Biotech President Sells $1.2M in Stock, But Bullish Stance Remains Intact

Adaptive Biotechnologies' president sold $1.21M in shares via pre-planned transaction, yet retains substantial holdings. Stock up 51% annually as core MRD business surges.
ADPTbiotechnologyinsider sale